Latest News
14
2023
Sep
Greenyn Biotechnology's "Insumate® Patent Amino Peptide Sequence mcIRBP-19" Bitter Melon Extract Granted New Dietary Ingredient (NDI) Approval by the U.S. FDA
Taipei, Taiwan – Greenyn Biotechnology (6846) is proud to announce that its exclusive "Insumate® Patented Amino Peptide Sequence mcIRBP-19" bitter melon extract has received approval from the United States Food and Drug Administration (FDA) as a New Dietary Ingredient (NDI). This significant achievement comes after 12 years of dedicated research and collaboration with prestigious medical institutions in Taiwan.
What sets "Insumate®" apart is its compliance with the rigorous safety standards set by the FDA, making it the first bitter melon extract to obtain this certification. Greenyn Biotechnology's "Insumate®" utilizes a high-efficiency patented production process to create a peptide with a molecular weight of only 2,162 Da, distinguishing it from typical hydrolyzed large-molecule bitter melon peptides with molecular weights often exceeding 10,000 Da and unclear compositions.
Backed by six scientific publications, "Insumate®" not only elucidates its mechanism of action but also demonstrates its efficacy through two large-scale clinical trials, earning 19 international patents and recognition from the world's top three invention awards. Substantiating its effectiveness in promoting metabolism, regulating physiological functions, and supporting overall health.
Its recent FDA NDI safety certification further ensures its safety for consumption, giving it a unique competitive edge in the market as the preferred bitter melon extract for metabolic regulation.
"Insumate® Patented Amino Peptide Sequence mcIRBP-19" marks Greenyn Biotechnology's second FDA NDI approval, following "Antromax® Antrodia Cinnammomea Mycelia." This achievement underscores Greenyn Biotechnology's commitment to showcasing Taiwan's health supplement ingredient innovations on the international stage and reinforces the company's dedication to delivering safe and trusted products that consumers can rely on.
At present, “Insumate® Patented Amino Peptide Sequence mcIRBP-19" has been licensed to various major brands for the production of dietary supplements. Products will bear the 'Insumate®' label and laser anti-counterfeiting labels to help consumers identify genuine products and make informed choices," said Greenyn Biotech.
News URL
1. Yahoo！新聞
2. 蕃薯藤yamNews
3. 台灣好新聞
4. HiNet新聞
5. 台灣產經新聞網
